Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection
Xianzhen Wei,Linlin Li,Meng Li,Hongjie Liang,Yu He,Shan Li
DOI: https://doi.org/10.2147/IDR.S396428
2023-01-19
Infection and Drug Resistance
Abstract:Xianzhen Wei, &ast Linlin Li, &ast Meng Li, Hongjie Liang, Yu He, Shan Li Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shan Li, Email Purpose: The rising incidence of carbapenem-resistant Pseudomonas aeruginosa (PA) bloodstream infection (BSI) has made the selection of antibiotic therapy more difficult and caused high mortality. This study was aimed at exploring the risk factors for carbapenem-resistant Pseudomonas aeruginosa (CRPA) bloodstream infection and identifying the risk factors for the outcomes of patients with PA-BSI. Methods: We performed a retrospective cohort study of patients with PA-BSI in a tertiary hospital from January 2017 to December 2021 in China. Epidemiological, clinical, and microbiological characteristics were described. Risk factors for CRPA-BSI and the outcomes of PA-BSI inpatients were identified, using multivariate logistic regression analysis. Results: A total of 198 PA-BSI inpatients were included. The negative outcome rate was significantly higher in patients infected with CRPA (15/34, 44.12%) than with carbapenem-susceptible Pseudomonas aeruginosa (CSPA) (35/164, 21.34%), and the difference was statistically significant (P=0.005). Multivariate logistic regression analysis showed that previous exposure to carbapenem (OR 3.519, 95% CI 1.359– 9.110, P=0.010) was an independent risk factor for CRPA-BSI. In addition, CRPA (OR 1.615, 95% CI 0.626– 4.171, P=0.32) was not an independent risk factor for negative outcome among PA-BSI inpatients. Conclusion: Our study showed that previous exposure to carbapenem was an independent risk factor for CRPA-BSI. CRPA was not an independent risk factor for a negative outcome in PA-BSI inpatients. Keywords: carbapenem-resistant, Pseudomonas aeruginosa bloodstream infection, risk factors, outcomes Pseudomonas aeruginosa is one of the mainly Gram-negative bacteria (GNB) species associated with nosocomial infections that cause high morbidity and mortality rates. 1,2 Indeed, the mortality rate of PA bloodstream infection reportedly ranges from 20% to 50%. 1,3,4 With the widespread use of broad-spectrum antibiotics, CRPA, multidrug-resistant (MDR) and extensively drug-resistant (XDR) PA isolates are gradually increasing. 5,6 According to the China Antimicrobial Surveillance Network ( https://www.chinets.com/Data/GermYear ), the resistance rates of imipenem and meropenem in PA infections were 23.6% and 20.9% in 2017, and 23% and 18.9% in 2021, respectively. The resistance rates of imipenem and meropenem in China have slightly decreased over the past 5 years but remained at a high level. Carbapenem antibiotics are commonly used for the treatment of PA infection and their high resistance rates limit the choices of antimicrobial therapy. 7 Despite a great deal of research on epidemiology, the incidence of CRPA remains high, and support for CRPA infection management remains insufficient. Meanwhile, risk factors for the outcomes of patients with PA infection remain unclear. Recio et al reported that inappropriate empirical therapy, XDR isolate, severe neutropenia and septic shock were associated with high mortality in PA bacterial pneumonia. 8 Teelucksingh et al identified that septic shock, age and Pitt bacteremia score ≥4 were risk factors for poor outcome in PA-BSI. 9 Recognizing the risk factors for the prognosis of patients with PA infection is important, so that special attention would be paid to patients with these risk factors to improve the prognosis. Therefore, our study aimed at exploring the epidemiology, clinical characteristics, antimicrobial resistance, and risk factors of patients with CRPA-BSI, we also identified the risk factors for the outcomes of patients with PA-BSI. This study may provide clues for clinicians to take special measures to curb the spread of CRPA and adjust their treatment strategies. This was a retrospective study conducted at the First Affiliated Hospital of Guangxi Medical University (2750-bed) from January 2017 to December 2021. Data from patients with PA-BSI were collected, including patients' demographic and clinical characteristics, comorbidities, laboratory examination, invasive procedures, antibiotics' exposure and outcomes. The inclusion criteria were as follows: the first episode of PA occurred during the study period, and patients met the diagnostic criteria for bloodstream infection, only the first episode of PA-BSI was included, and recurrent infections were excluded. In addition, outpatients and incomplete or missing me -Abstract Truncated-
pharmacology & pharmacy,infectious diseases